Historical record - last NADAC publication: 10/23/2019

Product Information

RIVASTIGMINE 1.5 MG CAPSULE is a generic product labeled by Nivagen Pharmaceuticals Inc., priced at $0.3616 per EA under NDC 75834013305. Its NADAC has been published 95 times since Feb 14, 2018.

The High Outlier badge above means this manufacturer's average price in the RIVASTIGMINE TARTRATE market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.

RIVASTIGMINE 1.5 MG CAPSULE

RIVASTIGMINE TARTRATE
$0.3616per EA
High Outlier

Strength

1.5 mg/1

NDC

75834013305

Classification

Generic

Dosage Form

CAPSULE

Route

ORAL

Last Updated

10/23/2019

Active Ingredients

RIVASTIGMINE TARTRATE

Approval Type

Generic (ANDA)

FDA Application

ANDA203844

On Market Since

9/4/2017

Pharmacological Classes

Cholinesterase Inhibitor
Cholinesterase Inhibitors

Price Statistics

The NADAC for RIVASTIGMINE 1.5 MG CAPSULE has been published 95 times since Feb 14, 2018, and over the history we have for it it has declined 45.9%. The table below summarizes its recorded NADAC range and movement.

Current price$0.3616 per EA
All-time high$0.9925 (Apr 11, 2018)
All-time low$0.2616 (Mar 20, 2019)
Median price$0.3876
Average price$0.4621
Largest weekly change+44.1% (Apr 17, 2019)
Weeks tracked95
Tracking sinceFeb 14, 2018

Price History

1W

0.0%

1M

0.0%

3M

0.0%

6M

0.0%

1Y

0.0%

3Y

0.0%

5Y

0.0%

All

-45.9%

Generic Alternatives

The matcher finds 2 NADAC-published products sharing this drug's active ingredient, strength, and dosage form across 2 manufacturers (up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 57% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Frequently asked questions

What is the NADAC price of RIVASTIGMINE 1.5 MG CAPSULE?

The current National Average Drug Acquisition Cost (NADAC) for RIVASTIGMINE 1.5 MG CAPSULE, manufactured by Nivagen Pharmaceuticals Inc., is $0.3616 per EA (NDC 75834013305), effective Dec 4, 2019.

How has the price of RIVASTIGMINE 1.5 MG CAPSULE changed over time?

Over the history we have for it, the NADAC for RIVASTIGMINE 1.5 MG CAPSULE has declined 45.9%. It has been tracked across 95 weekly CMS publications since Feb 14, 2018.

What are the highest and lowest recorded NADAC prices for RIVASTIGMINE 1.5 MG CAPSULE?

Since Feb 14, 2018, the NADAC for RIVASTIGMINE 1.5 MG CAPSULE has ranged from a low of $0.2616 (Mar 20, 2019) to a high of $0.9925 (Apr 11, 2018), with a median of $0.3876 per EA.

Are there cheaper alternatives to RIVASTIGMINE 1.5 MG CAPSULE?

Yes. 2 NADAC-published products share the same active ingredient, strength, and dosage form. The lowest-priced option, RIVASTIGMINE 1.5 MG CAPSULE, is $0.1542 per EA — about 57% below RIVASTIGMINE 1.5 MG CAPSULE.

Who manufactures RIVASTIGMINE 1.5 MG CAPSULE?

RIVASTIGMINE 1.5 MG CAPSULE (NDC 75834013305) is labeled by Nivagen Pharmaceuticals Inc., and CMS classifies it as a generic product.